

Quarterly Performance Update

Q2 FY-17

Kaya Limited



1

Disclaimer

This investor presentation has been prepared by Kaya Limited ("Kaya") and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer.

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the general business plans and strategy of Kaya, its future financial condition and growth prospects, future developments in its industry. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to risks with respect to its skin care business.

Kaya may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

No person is authorized to give any information or to make any representation not contained in and not consistent with this presentation and, if given or made, such information or representation must not be relied upon as having been authorized by or on behalf of Kaya.





Kaya Group : Key Highlights – Q2 FY 17


- Net Revenue (NR) for Q2 FY 17 at INR 1022 Mn has grown by 16%. Same store growth (SSG: 13%)
 - SSG @ constant currency is 11%
- **EBIDTA** of INR 48 Mn (5% of NR) compared to EBIDTA of INR 32 Mn (4% of NR) in Q2 FY 16, growth of 48%, majorly due to better performance of new clinics & reduction in losses in Kaya India.
- PAT at INR 27 Mn (3% of NR) as compared to INR 26 Mn (3% of NR) in Q2 FY 16, 3% growth due to increased


depreciation & lower other income .


Financial Summary – Q2 FY17













Awards & Recognition

India –

• "Healthcare Excellence Awards- CIMS" – Award for Best Cosmetic Solution Provider Co.

• "Asia Awards for Excellence in Branding & Marketing- CMO" - Award for Best Loyalty Program & Brand Excellence in Beauty, Wellness Sector

• "Digital campaign of the year" – Award for Best online /Digital Marketing Campaign



Kaya India Region



a™


love what you see™

Kaya India : Key Highlights

- Net Revenue for Q2 FY 17 at INR 492 Mn has grown by 8% (SSG:5%)
 - **Ecommerce** NR at Rs 8 Mn grew by 113% over Q2 LY, contributing 9% of Product revenue.
- EBIDTA at INR (19) Mn (-4% of NR) compared to EBIDTA of INR (29) Mn (-6% to NR) in Q2 LY.,
 - EBDITA loss reduced by 35% due to better performance of new clinics
- PAT is INR (20) Mn (-4 of NR) against LY Q2 profit of INR (19) Mn (-4% of NR)
- Key Initiatives :
 - Launch of Hair Care services across 72 Clinics
 - Rollout of E-Consultation model .




Our Presence in India



The picture above just gives an idea of location and don't represent exact scale




Operational Indicators – India (clinics only)



- Customer count grew by 8% over LY. (SSG: 3.5%)
- Ticket size growth flat.



Category Mix % - India (clinics only)



- Cure category has grown by 7% (SSG: 2%) in Q2 FY 17
- Care Category (Facials) grew by 28% (SSG: 24%) in Q2 FY 17
- In Clinic Product sales de-grew by 1% (SSG: 4%) in Q2 FY 17.
- Products category (including KSB formats) grew by 12%,
 - KSB as a product channel has grown by 74% over LY -Q2.



10







Kaya Middle East : Key Highlights

- Net Revenue at INR 530 Mn for Q2 FY 17 has grown by 24%. Same store growth (SSG : 20%).
 - SSG @ constant currency for Q2 FY 17 is 16%
- Ticket size grew by 5% over Q2 FY 16
- EBIDTA of INR 67 Mn (13% of NR) compared to EBIDTA of INR 61 Mn (14% of NR) in Q2 FY 16
- PAT at INR 47 Mn (9% of NR) is same as INR 45 Mn (10% of NR) in Q2 FY 16
- <u>New initiative</u>
- In September 2016, Kaya Middle East DMCC, has entered into a agreement for acquiring 75% beneficial interest in two clinics a Minal Medical Centre, Dubai and Minal Specialized Clinic Dermatology, Sharjah. Both of the Company is in the process of fulfilling certain conditions precedent and obtaining the requisite statutory approvals for acquisition to be effective.




Our Presence in GCC...






Operational Indicators – Middle East



On constant currency basis



Category Mix % - KME Region



- Cure category has grown by 13% (SSG: 8%) in Q2 FY 17.
 - Hair free technology scale up in all clinics helped to drive growth.
- Care category grew by 7% (SSG: 2%) in Q2 FY 17
- Product category de-grew by 4% (SSG: -1%) in Q2 FY 17


On constant currency basis








Financial Highlights : Kaya Group






Financial Highlights : India





Financial Highlights : Middle East



PAT at 9% against 10% in Q2 LY



In case of any clarifications please contact on

investorrelations@kayaindia.net



Thank you



21

